Paris - Delayed Quote EUR

Inventiva S.A. (IVA.PA)

Compare
2.1400
0.0000
(0.00%)
At close: January 10 at 5:35:21 PM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for IVA.PA

Recent News: IVA.PA

View More
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 25 days ago
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
GlobeNewswire 26 days ago
Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024

Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024
GlobeNewswire 30 days ago
Inventiva reports 2024 Third Quarter Financial Information¹

Inventiva reports 2024 Third Quarter Financial Information¹
GlobeNewswire last month
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents

Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
GlobeNewswire last month
Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024

Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024
GlobeNewswire last month
The first MASH drug could open the door for others — including GLP-1s

The first MASH drug could open the door for others — including GLP-1s
Pharma Voice last month
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
GlobeNewswire last month
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH

Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
GlobeNewswire 2 months ago
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
GlobeNewswire 2 months ago
Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data

Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data
BioPharma Dive 2 months ago
View More

Related Tickers

MEB.F MedinCell S.A.
16.54
-0.96%
 
ABNX.PA ABIONYX Pharma SA
1.2800
-0.16%
 
ABVX.PA ABIVAX Société Anonyme
6.47
+2.21%
 
TNG.PA Transgene SA
0.7590
+2.43%
 
NANO.PA Nanobiotix S.A.
2.9700
+0.68%
 
HYL.BR Hyloris Pharmaceuticals SA
6.08
0.00%
 
ARMP Armata Pharmaceuticals, Inc.
2.0894
+0.94%
 
KRRO Korro Bio, Inc.
35.26
-6.27%
 
DBV.PA DBV Technologies S.A.
0.8750
-23.91%
 
ARGX.BR argenx SE
644.00
+0.25%